Beijing GeneCradle Technology Co., Ltd. has completed the supplementary submission of information for its new gene therapy drug GC304 adeno-associated virus injection for the treatment of severe hypertriglyceridemia, and its clinical trial application was accepted by the Drug Review Center of the China Food and Drug Administration on September 2, 2022.

About GeneCradle
Beijing GeneCradle Technology Co., Ltd. is a biotechnology platform company focusing on the innovative research and development of gene therapy drugs. It focuses on the research and development of gene therapy products in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases mediated by AAV vector delivery technology. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, and is committed to turning "incurable" into "once and for all" cures, benefiting patients and their families. Through the research and development and clinical application of rare disease gene drugs, we have a deeper understanding of life and health, and transition to the treatment and rehabilitation of chronic diseases and other major diseases.